Aadi Bioscience reports Q3 EPS (60c), consensus (72c)

Reports Q3 revenue $5.96M, consensus $6.61M. Cash, cash equivalents and short-term investments as of September 30, were $119.3M as compared to $172.6M as of December 31, 2022, which is expected to fund operations into 2025 based on current plans. “The Q3 was marked by strong execution by our Aadi Bio team. Our PRECISION1 tumor-agnostic trial continued rapid enrollment, and we look forward to sharing an early interim analysis on the first third of patients by mid-December,” said Dave Lennon, President and CEO of Aadi Bioscience. “FYARRO continued to demonstrate the importance of a tumor-targeting mTOR inhibitor for PEComa patients, and we are progressing in our previously announced development strategy with the initiation of new Phase 2 studies for endometrial cancer and in neuroendocrine tumors.”